WuXi XDC Cayman Inc.

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
19.06 ^USD	+0.63%		-17.31%	-40.44%

10:13am	WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	DJ
May. 01	WuXi XDC Cayman’s Profit Up 82% in 2023	MT

WuXi XDC Cayman Inc. Provides Earnings Guidance for the Year Ended December 31, 2023

January 31, 2024 at 05:07 pm EST

WuXi XDC Cayman Inc. provided earnings guidance for the year ended December 31, 2023. It is expected that the Group will record an increase of over 100% in revenue; an increase of over 80% in net profit; and an increase of over 100% in adjusted net profit, as compared with those for the corresponding period of last year. The Company considers that such expected increase was primarily attributable to the continuous active development of antibody-drug conjugate (``ADC'') industry and the Group's unique competitive strengths in winning projects.

Latest news about WuXi XDC Cayman Inc.

WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	04:13am	DJ
WuXi XDC Cayman’s Profit Up 82% in 2023	May. 01	MT
WuXi XDC Cayman Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 24	CI
WuXi Shares Fall as Washington Lobbying Group Cuts Ties	Mar. 14	DJ
WuXi XDC Cayman’s Shares Close 10% Lower Amid Fear of Potential U.S. Sanctions	Mar. 07	MT
WuXi Companies' Shares Fall Amid Renewed U.S. Sanction Concerns	Mar. 07	DJ
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions	Mar. 04	DJ
WuXi Shares Hit by U.S. Committee Seeking Inquiry, Blacklisting	Feb. 14	DJ
US lawmakers call for sanctions on China's WuXi AppTec biotech firm	Feb. 12	RE
WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill	Feb. 02	DJ
WuXi XDC Forecasts 80% Rise in 2023 Profit; Shares Jump 9%	Jan. 31	MT
WuXi XDC Cayman Inc. Provides Earnings Guidance for the Year Ended December 31, 2023	Jan. 31	CI
Wuxi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development	Jan. 30	CI
MGI Tech Responds to US BIOSECURE Act	Jan. 29	MT
Wuxi Biologics Clarifies CEO Background Following US Draft Bill	Jan. 29	MT
WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate	Jan. 28	DJ
WuXi AppTec Says Findings of U.S. Draft Bill Against Company Aren't Accurate	Jan. 28	DJ
WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech -- Update	Jan. 26	DJ
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates	Jan. 23	CI
Wuxix XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development	Jan. 02	CI
WuXi XDC Says Confident of Meeting Growth Target	Dec. 05	MT
Alibaba's Scrapped Spin-Off Plan Drags Down Hong Kong Stocks; WuXi XDC Cayman Gains 36% at Debut	Nov. 17	MT
WuXi Biologics Arm WuXi XDC Lists on HKEX	Nov. 17	MT
Wuxi XDC Cayman Shares Surge on Hong Kong Debut -- Update	Nov. 17	DJ
WuXi XDC Cayman Inc. has completed an IPO in the amount of HKD 3.675988 billion.	Nov. 16	CI

Chart WuXi XDC Cayman Inc.

Duration

Period

More charts

Company Profile

WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.62 CNY

Average target price

28.8 CNY

Spread / Average Target

+63.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
WUXI XDC CAYMAN INC.	-40.44%	2.87B
ELI LILLY AND COMPANY	+29.34%	684B
NOVO NORDISK A/S	+29.59%	568B
JOHNSON & JOHNSON	-3.86%	361B
MERCK & CO., INC.	+18.27%	329B
ABBVIE INC.	+4.63%	284B
ASTRAZENECA PLC	+16.08%	240B
NOVARTIS AG	+9.47%	208B
ROCHE HOLDING AG	-6.91%	200B
AMGEN INC.	+7.96%	166B

Other Pharmaceuticals